Victoria Socha

DocwireNews

Spring Clinical Meetings 2021Growth of kidney cysts in autosomal dominant polycystic <a href="https://www.docwirenews.com/nephtimes/nephtimes-conferences/nephtimes-spring-clinical-meetings-nkf/raising-awareness-about-gout-and-chronic-kidney-disease/">kidney</a> disease (ADPKD) was inhibited with metformin in both in vitro and in vivo ADPKD models. Results of TAME PKD, a phase 2, parallel-group, randomized, double-blind, placebo-controlled trial, were reported by Ronald Perrone, MD, during a virtual <a href="https://casehippo.com/spa/symposium/national-kidney-foundation-2021-spring-clinical-meetings/event/gallery/?search=Ronald%20Perrone">poster</a> session at the NKF 2021 Spring Clinical Meetings. The poster was titled A Randomized Trial of Administration of Metformin in PKD (TAME PKD).The primary outcomes of interest in TAME PKD were the tolerability, safety, and preliminary efficacy of metformin in ADPKD.TAME PKD enrolled 97 participants from June 2016 to December 2018. Inclusion criteria were age 18 to 60 years, and estimated glomerular filtration rate (eGFR) &gt;50 mL/min/1.73 m2.Medication tolerability was defined by (1) gastrointestinal symptoms assessed using the Gastrointestinal Symptoms Rating Scale (GSRS, range 1-7); (2) response to &ldquo;Can you tolerate this dose of the study drug for the rest of your life?&rdquo;; and (3) maximally tolerated dose at 24 months. Safety was defined by adverse events and serious adverse events, including prospectively defined hypoglycemia and lactic acidosis. The primary safety outcome was based on the proportion of study participants who experienced at least one serious adverse event during 24 months of study follow-up.At baseline, the GSRS was low in both the metformin group and the placebo group; there was no significant change in GSRS over time. The highest achieved dose of 2000 mg was similar between the two groups: 67% in the Metformin group and 81% in the placebo group.Dose was reduced in 23 participants in the metformin group (43%) due to inability to tolerate versus 14 participants in the placebo group (29%). Proportions of participants who withdrew from the study were similar in the two groups. The proportion of participants experiencing at least one serious adverse event was also similar between the groups.Mean annual percent change in height adjusted total kidney volume was 1.68% more in the metformin group compared with the placebo group. The 24-month decline in eGFR was 2.73 mL/min/1.73 m2 greater in the placebo group than in the metformin group.In conclusion, the researchers said, &ldquo;The TAME PKD study has demonstrated tolerability and safety of metformin in ADPKD. Demonstration of efficacy to slow progression will require a larger study enriched in participants at risk of rapid progression.&rdquo;Source: Perrone R, Abebe K, Watnick T, et al. A randomized trial of administration of metformin in PKD (TAME PKD). Abstract of a poster presented at the National Kidney Foundation virtual 2021 Spring Clinical Meetings (Abstract #331), April 9, 2021.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

TAME PKD Results: Phase 2 Trial of Metformin in ADPKD

ADPKD

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe